Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05243511 · ClinicalTrials.gov registry record · Phase 3
Prospective Study to Evaluate a Digital Regimen for Fibromyalgia Management
A Phase 3 study, sponsored by Swing Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 275
- Enrollment target
NCT05243511 is a Phase 3 study that has completed, run by Swing Therapeutics. The registered enrollment target is 275 participants.
The verdict
NCT05243511, a Phase 3 study, has completed, sponsored by Swing Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 275 participants
- Enrollment target
Study Summary
PROSPER-FM is a multi-center, randomized, non-significant risk device study to evaluate the safety and efficacy of two digital therapy smartphone applications in participants with fibromyalgia. Eligible participants are randomized (1:1) to either the Digital Acceptance and Commitment Therapy (Digital ACT) group or the Digital Symptom Tracker group and receive assigned therapy for 12 weeks.
Interventions
- DEVICE Digital ACT
- OTHER Digital Symptom Tracker
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 275 participants |
| Start Date | 2022-02-08 |
| Est. Completion | 2023-05-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05243511
The ClinicalTrials.gov registry entry for NCT05243511 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 275 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Swing Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Digital ACT is the first listed.
NCT05243511 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05243511 about?
NCT05243511 is a clinical study titled "Prospective Study to Evaluate a Digital Regimen for Fibromyalgia Management". PROSPER-FM is a multi-center, randomized, non-significant risk device study to evaluate the safety and efficacy of two digital therapy smartphone applications in participants with fibromyalgia. Eligible participants are randomized (1:1) to either the Digital Acceptance and Commitment Therapy (Digita...
What is the current status of trial NCT05243511?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 275 participants. The study started on 2022-02-08. Estimated completion is 2023-05-15.
What interventions are being tested in trial NCT05243511?
The interventions under investigation include: Digital ACT (DEVICE), Digital Symptom Tracker (OTHER).
Who is sponsoring clinical trial NCT05243511?
This trial is sponsored by Swing Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.